Mayo Clinic enters into drug partnership
Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute to develop new drugs.
Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms at Sanford-Burnham facilities.
"The collaboration provides an avenue for Mayo scientists to rapidly translate basic science discoveries into screening platforms that will enable new drug discovery and a new paradigm in drug development," said Dr. Andrew Badley, Mayo Clinic's associate dean for research resources.
The agreement builds on a preliminary pilot program involving six projects in 2012, ranging from cancer to immunology to neurology studies. That effort was supported by Mayo Clinic's Center for Translational Science Activities, the Mayo Clinic Cancer Center, the Mayo Center for Individualized Medicine, and the Mayo Center for Regenerative Medicine.
The coming year will see an even broader scope of projects.
"We look forward to further engaging with our Mayo Clinic colleagues as we develop innovative screens to identify chemical compounds that modulate the activity of clinically relevant targets," said Dr. Michael Jackson, Ph.D., vice president of drug discovery and development at Sanford-Burnham. "If successful, these compounds will form the basis of completely novel 'first in class' therapies."
Sanford-Burnham Sanford-Burnham is a nonprofit independent medical research institute with operations in San Diego and Orlando.